MX2020004431A - Anticuerpos y metodos de uso. - Google Patents

Anticuerpos y metodos de uso.

Info

Publication number
MX2020004431A
MX2020004431A MX2020004431A MX2020004431A MX2020004431A MX 2020004431 A MX2020004431 A MX 2020004431A MX 2020004431 A MX2020004431 A MX 2020004431A MX 2020004431 A MX2020004431 A MX 2020004431A MX 2020004431 A MX2020004431 A MX 2020004431A
Authority
MX
Mexico
Prior art keywords
cancer
antibodies
methods
crtam
nucleic acids
Prior art date
Application number
MX2020004431A
Other languages
English (en)
Inventor
Arnima Bisht
Rachel Dusek
Haining Huang
Chuck Hannum
James Ackroyd
Livija Deban
Original Assignee
Oxford Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biotherapeutics Ltd filed Critical Oxford Biotherapeutics Ltd
Publication of MX2020004431A publication Critical patent/MX2020004431A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe en la presente descripción anticuerpos dirigidos contra CRTAM, ácidos nucleicos que codifican tales anticuerpos, células huésped que comprenden tales ácidos nucleicos que codifican el anticuerpo, métodos para preparar anticuerpos anti-CRTAM y métodos para el tratamiento de enfermedades, por ejemplo, cánceres humanos, que incluyen pero no se limitan a cáncer de pulmón de células pequeñas, cáncer de pulmón de células no pequeñas (incluyendo carcinomas escamosos y adenocarcinomas), cáncer de piel, incluyendo melanoma, cáncer de mama (incluido TNBC), cáncer colorrectal, cáncer gástrico, cáncer de ovario, cáncer de cuello uterino, cáncer de próstata, cáncer de riñón, cáncer de hígado, incluido carcinoma hepatocelular, cáncer de páncreas, cáncer de 10 cabeza y cuello, cáncer de nasofaringe, cáncer de esófago, cáncer de vejiga y otros cánceres uroepiteliales, cáncer de estómago, glioma, glioblastoma, cáncer testicular, cáncer de tiroides, cáncer de hueso, cáncer de vesícula biliar y de conductos biliares, cáncer uterino, cáncer suprarrenal, sarcomas, GIST, tumores neuroendocrinos y neoplasias hematológicas.
MX2020004431A 2017-11-02 2018-11-01 Anticuerpos y metodos de uso. MX2020004431A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762580667P 2017-11-02 2017-11-02
US201862697145P 2018-07-12 2018-07-12
PCT/GB2018/053165 WO2019086878A1 (en) 2017-11-02 2018-11-01 Antibodies and methods of use

Publications (1)

Publication Number Publication Date
MX2020004431A true MX2020004431A (es) 2020-08-06

Family

ID=64267853

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004431A MX2020004431A (es) 2017-11-02 2018-11-01 Anticuerpos y metodos de uso.

Country Status (12)

Country Link
US (2) US11673963B2 (es)
EP (1) EP3704154A1 (es)
JP (1) JP7430137B2 (es)
KR (1) KR20200074127A (es)
CN (1) CN111295395A (es)
AU (1) AU2018361819A1 (es)
BR (1) BR112020008438A2 (es)
CA (1) CA3079313A1 (es)
IL (1) IL274376A (es)
MX (1) MX2020004431A (es)
WO (1) WO2019086878A1 (es)
ZA (1) ZA202002144B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230416364A1 (en) 2020-08-13 2023-12-28 Bristol-Myers Squibb Company Methods of redirecting of il-2 to target cells of interest
TW202317631A (zh) * 2021-06-30 2023-05-01 大陸商南京聖和藥業股份有限公司 抗crtam抗體及其應用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
EP1411851B1 (en) 2001-08-03 2006-11-02 Tyco Healthcare Group LP Marker for use with a tissue marking apparatus
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7267960B2 (en) * 2003-07-25 2007-09-11 Amgen Inc. Antagonists and agonists of LDCAM and methods of use
ES2669510T3 (es) 2004-09-23 2018-05-28 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
CN101854949A (zh) * 2007-08-30 2010-10-06 健泰科生物技术公司 用于调控t细胞的方法和组合物
ES2865735T3 (es) 2013-01-28 2021-10-15 Evec Inc Anticuerpo anti-hmgb1 humanizado o fragmento de unión a antígeno del mismo
RU2016101109A (ru) * 2013-07-15 2017-08-18 Дзе Боард Оф Трастис Оф Дзе Лилэнд Стэнфорд Джуниор Юниверсити Медицинское применение агонистов cd38
US20170022286A1 (en) * 2015-03-23 2017-01-26 The Board Of Trustees Of The Leland Stanford Junior University Medical uses of crtam agonists

Also Published As

Publication number Publication date
US20200262927A1 (en) 2020-08-20
BR112020008438A2 (pt) 2020-10-20
KR20200074127A (ko) 2020-06-24
US20240132614A1 (en) 2024-04-25
AU2018361819A1 (en) 2020-04-16
IL274376A (en) 2020-06-30
CA3079313A1 (en) 2019-05-09
US11673963B2 (en) 2023-06-13
ZA202002144B (en) 2021-04-28
JP2021501583A (ja) 2021-01-21
WO2019086878A1 (en) 2019-05-09
EP3704154A1 (en) 2020-09-09
JP7430137B2 (ja) 2024-02-09
CN111295395A (zh) 2020-06-16

Similar Documents

Publication Publication Date Title
CY1121085T1 (el) Αντισωματα για θεραπευτικη αγωγη καρκινου που εκφραζει κλαυδινη 6
CY1120300T1 (el) Αντισωματα ειδικα στην κλαουδινη 6 (cldn6)
HRP20201066T1 (hr) Anti-pvrig antitijela i postupci uporabe
PH12019501959A1 (en) Therapeutic rna
MX2020008103A (es) Metodos y composiciones para polarizacion de macrofagos.
NZ724368A (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2016161410A3 (en) Treatment of cancer using inhibitors of tgf-beta and pd-1
EA201890294A1 (ru) Химерный полипептидный комплекс и способы его получения и применения
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
JP2018507249A5 (es)
MX2022009170A (es) Procedimientos para el tratamiento del cancer con un anticuerpo antagonista anti-tigit.
RU2016107884A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
CY1120123T1 (el) Μονοκλωνικα αντισωματα κατα της gt468 για τη θεραπεια του καρκινου
MX2014013367A (es) Composiciones organicas para tratar enfermedades relacionadas con kras.
MX2020004431A (es) Anticuerpos y metodos de uso.
MX2013010379A (es) Uso de inhibidores de receptores de la familia egfr en el tratamiento de canceres de mama refractarios a hormonas.
WO2016123591A3 (en) Compositions and methods for treatment and detection of cancers
EP2582727A4 (en) ANTIBODIES AGAINST ENDOPLASMINE AND THEIR USE
MA39818A (fr) Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
DOP2022000016A (es) Terapia combinada con anticuerpos contra claudin 18.2 e inhibidores del punto de control inmune para el tratamiento del cáncer
IL288939A (en) Methods of treating cancer by targeting cold tumors
WO2014198919A3 (en) Tumor marker, monoclonal antibodies and methods of use thereof
PH12015502757A1 (en) Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
PH12016502298A1 (en) Vegfr2/ang2 compounds
EA202090638A1 (ru) Антитела и способы применения